Cargando…

Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy

OBJECTIVE: To retrospectively evaluate the outcomes of patients with low and intermediate risk thyroid carcinoma treated with total thyroidectomy (TT) and who did not undergo radioiodine remnant ablation (RRA) and to compare them to patients receiving low dose of iodine (30 mCi). SUBJECTS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Súss, Shirlei Kugler Aiçar, Mesa, Cleo Otaviano, de Carvalho, Gisah Amaral, Miasaki, Fabíola Yukiko, Chaves, Carolina Perez, Fuser, Dominique Cochat, Corbo, Rossana, Momesso, Denise, Bulzico, Daniel A., Graf, Hans, Vaisman, Fernanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Endocrinologia e Metabologia 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118992/
https://www.ncbi.nlm.nih.gov/pubmed/29641738
http://dx.doi.org/10.20945/2359-3997000000025
_version_ 1785028925450092544
author Súss, Shirlei Kugler Aiçar
Mesa, Cleo Otaviano
de Carvalho, Gisah Amaral
Miasaki, Fabíola Yukiko
Chaves, Carolina Perez
Fuser, Dominique Cochat
Corbo, Rossana
Momesso, Denise
Bulzico, Daniel A.
Graf, Hans
Vaisman, Fernanda
author_facet Súss, Shirlei Kugler Aiçar
Mesa, Cleo Otaviano
de Carvalho, Gisah Amaral
Miasaki, Fabíola Yukiko
Chaves, Carolina Perez
Fuser, Dominique Cochat
Corbo, Rossana
Momesso, Denise
Bulzico, Daniel A.
Graf, Hans
Vaisman, Fernanda
author_sort Súss, Shirlei Kugler Aiçar
collection PubMed
description OBJECTIVE: To retrospectively evaluate the outcomes of patients with low and intermediate risk thyroid carcinoma treated with total thyroidectomy (TT) and who did not undergo radioiodine remnant ablation (RRA) and to compare them to patients receiving low dose of iodine (30 mCi). SUBJECTS AND METHODS: A total of 189 differentiated thyroid cancer (DTC) patients treated with TT followed by 30mCi for RRA or not, followed in two referral centers in Brazil were analyzed. RESULTS: From the 189 patients, 68.8% was ATA low-risk, 30.6% intermediate and 0.6% high risk. Eighty-seven patients underwent RRA and 102 did not. The RRA groups tended to be younger and had a higher frequency of extra-thyroidal extension (ETE). RRA did not have and impact on response to initial therapy neither in low (p = 0.24) nor in intermediate risk patients (p = 0.66). It also had no impact on final outcome and most patients had no evidence of disease (NED) at final follow-up. Recurrence/persistence of disease was found in 1.2% of RRA group and 2% in patients treated only with TT (p = 0.59). CONCLUSIONS: Our study shows that in low and intermediate-risk patients, RRA with 30 mCi seems to have no major advantage over patients who did not undergo RRA regarding response to initial therapy in each risk group and also in long term outcomes.
format Online
Article
Text
id pubmed-10118992
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Sociedade Brasileira de Endocrinologia e Metabologia
record_format MEDLINE/PubMed
spelling pubmed-101189922023-04-22 Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy Súss, Shirlei Kugler Aiçar Mesa, Cleo Otaviano de Carvalho, Gisah Amaral Miasaki, Fabíola Yukiko Chaves, Carolina Perez Fuser, Dominique Cochat Corbo, Rossana Momesso, Denise Bulzico, Daniel A. Graf, Hans Vaisman, Fernanda Arch Endocrinol Metab Original Article OBJECTIVE: To retrospectively evaluate the outcomes of patients with low and intermediate risk thyroid carcinoma treated with total thyroidectomy (TT) and who did not undergo radioiodine remnant ablation (RRA) and to compare them to patients receiving low dose of iodine (30 mCi). SUBJECTS AND METHODS: A total of 189 differentiated thyroid cancer (DTC) patients treated with TT followed by 30mCi for RRA or not, followed in two referral centers in Brazil were analyzed. RESULTS: From the 189 patients, 68.8% was ATA low-risk, 30.6% intermediate and 0.6% high risk. Eighty-seven patients underwent RRA and 102 did not. The RRA groups tended to be younger and had a higher frequency of extra-thyroidal extension (ETE). RRA did not have and impact on response to initial therapy neither in low (p = 0.24) nor in intermediate risk patients (p = 0.66). It also had no impact on final outcome and most patients had no evidence of disease (NED) at final follow-up. Recurrence/persistence of disease was found in 1.2% of RRA group and 2% in patients treated only with TT (p = 0.59). CONCLUSIONS: Our study shows that in low and intermediate-risk patients, RRA with 30 mCi seems to have no major advantage over patients who did not undergo RRA regarding response to initial therapy in each risk group and also in long term outcomes. Sociedade Brasileira de Endocrinologia e Metabologia 2018-03-23 /pmc/articles/PMC10118992/ /pubmed/29641738 http://dx.doi.org/10.20945/2359-3997000000025 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Súss, Shirlei Kugler Aiçar
Mesa, Cleo Otaviano
de Carvalho, Gisah Amaral
Miasaki, Fabíola Yukiko
Chaves, Carolina Perez
Fuser, Dominique Cochat
Corbo, Rossana
Momesso, Denise
Bulzico, Daniel A.
Graf, Hans
Vaisman, Fernanda
Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
title Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
title_full Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
title_fullStr Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
title_full_unstemmed Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
title_short Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
title_sort clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mci for ablation or without radioactive iodine therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118992/
https://www.ncbi.nlm.nih.gov/pubmed/29641738
http://dx.doi.org/10.20945/2359-3997000000025
work_keys_str_mv AT sussshirleikugleraicar clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT mesacleootaviano clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT decarvalhogisahamaral clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT miasakifabiolayukiko clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT chavescarolinaperez clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT fuserdominiquecochat clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT corborossana clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT momessodenise clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT bulzicodaniela clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT grafhans clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy
AT vaismanfernanda clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy